

Marta Schirripa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1588775/publications.pdf>

Version: 2024-02-01

298
papers

23,440
citations

22099

59
h-index

8835

145
g-index

300
all docs

300
docs citations

300
times ranked

26101
citing authors

#	ARTICLE	IF	CITATIONS
1	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2013, 381, 303-312.	6.3	2,276
2	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1182-1191.	5.1	2,058
3	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 773-779.	0.8	1,525
4	Colorectal cancer. <i>Lancet</i> , The, 2010, 375, 1030-1047.	6.3	1,318
5	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1909-1919.	13.9	1,027
6	CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy. <i>Cancer Treatment Reviews</i> , 2018, 63, 40-47.	3.4	867
7	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 692-700.	0.8	686
8	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	3.8	670
9	<i>ERCC1</i> and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 4298-4304.	0.8	601
10	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 194.	3.4	555
11	Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2006, 24, 4914-4921.	0.8	504
12	FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab. <i>Journal of Clinical Oncology</i> , 2007, 25, 3712-3718.	0.8	466
13	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	385
14	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 1113-1122.	9.4	315
15	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 282-298.	12.5	312
16	Markers of Response for the Antiangiogenic Agent Bevacizumab. <i>Journal of Clinical Oncology</i> , 2013, 31, 1219-1230.	0.8	309
17	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , The, 2015, 16, 937-948.	5.1	286
18	A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 319-327.	5.7	285

#	ARTICLE	IF	CITATIONS
19	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. <i>Oncologist</i> , 2007, 12, 38-50.	1.9	218
20	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
21	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203
22	Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity. <i>Journal of the American Chemical Society</i> , 2018, 140, 16413-16417.	6.6	195
23	Molecular Pathways: Estrogen Pathway in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5842-5848.	3.2	181
24	Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab. <i>Clinical Cancer Research</i> , 2008, 14, 7554-7563.	3.2	179
25	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 805-812.	1.5	169
26	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1070-1082.	5.1	169
27	Gender Disparities in Metastatic Colorectal Cancer Survival. <i>Clinical Cancer Research</i> , 2009, 15, 6391-6397.	3.2	168
28	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014, 50, 57-63.	1.3	162
29	Outlooks on Epstein-Barr virus associated gastric cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 15-22.	3.4	149
30	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. <i>British Journal of Cancer</i> , 2015, 112, 1921-1928.	2.9	146
31	IL-33 activates tumor stroma to promote intestinal polyposis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2487-96.	3.3	141
32	First-line chemotherapy for mCRCâ€“a review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 607-619.	12.5	138
33	Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. <i>Annals of Oncology</i> , 2015, 26, 724-730.	0.6	136
34	Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. <i>Molecular Therapy</i> , 2020, 28, 536-547.	3.7	135
35	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018, 63, 48-60.	3.4	134
36	B cell and B cell-related pathways for novel cancer treatments. <i>Cancer Treatment Reviews</i> , 2019, 73, 10-19.	3.4	132

#	ARTICLE	IF	CITATIONS
37	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. <i>Oncologist</i> , 2018, 23, 1319-1327.	1.9	131
38	Role of <i>NRAS</i> mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015, 136, 83-90.	2.3	126
39	Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab. <i>Clinical Cancer Research</i> , 2008, 14, 7884-7895.	3.2	116
40	TAS-102, a novel antitumor agent: A review of the mechanism of action. <i>Cancer Treatment Reviews</i> , 2015, 41, 777-783.	3.4	115
41	Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1551-1556.	0.8	110
42	Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. <i>Gastroenterology</i> , 2020, 158, 1274-1286.e12.	0.6	110
43	Molecular insight of regorafenib treatment for colorectal cancer. <i>Cancer Treatment Reviews</i> , 2019, 81, 101912.	3.4	109
44	ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 162-6.	0.3	108
45	Relationship between <i>MLH1</i> , <i>PMS2</i> , <i>MSH2</i> and <i>MSH6</i> gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. <i>International Journal of Cancer</i> , 2020, 147, 2948-2956.	2.3	102
46	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 475-483.	0.7	97
47	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. <i>Cell Reports</i> , 2014, 7, 1940-1955.	2.9	90
48	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	3.2	90
49	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
50	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Nord Ovest (GONO). <i>Annals of Oncology</i> , 2013, 24, 2062-2067.	0.6	86
51	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011, 104, 1262-1269.	2.9	85
52	Molecular Pathways: Cachexia Signaling—A Targeted Approach to Cancer Treatment. <i>Clinical Cancer Research</i> , 2016, 22, 3999-4004.	3.2	85
53	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	2.0	82
54	Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5783-5792.	3.2	79

#	ARTICLE	IF	CITATIONS
55	First-line combination treatment of colorectal cancer with hepatic metastases: Choosing a targeted agent. <i>Cancer Treatment Reviews</i> , 2008, 34, S3-S7.	3.4	77
56	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011, 11, 247.	1.1	69
57	Immunotherapy in Gastrointestinal Cancers. <i>BioMed Research International</i> , 2017, 2017, 1-17.	0.9	69
58	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA3-LBA3.	0.8	68
59	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3096-3103.	3.2	65
60	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. <i>PLoS ONE</i> , 2013, 8, e66774.	1.1	64
61	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020, 5, e000682.	2.0	64
62	The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. <i>Cancer Cell International</i> , 2020, 20, 30.	1.8	63
63	Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. <i>Clinical Cancer Research</i> , 2015, 21, 5002-5007.	3.2	61
64	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 30-36.	2.9	56
65	A <i>let-7</i> microRNA-Binding Site Polymorphism in <i>KRAS</i> Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 4499-4510.	3.2	55
66	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020, 26, 5943-5951.	3.2	55
67	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. <i>British Journal of Cancer</i> , 2013, 108, 2549-2556.	2.9	51
68	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
69	Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). <i>Oncologist</i> , 2019, 24, 921-932.	1.9	51
70	Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3503-3503.	0.8	49
71	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. <i>Journal of Clinical Oncology</i> , 2017, 35, 519-519.	0.8	49
72	Colorectal cancer: epigenetic alterations and their clinical implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 439-448.	3.3	48

#	ARTICLE	IF	CITATIONS
73	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. <i>Cancer Cell International</i> , 2018, 18, 99.	1.8	48
74	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	2.8	48
75	All You Need to Know About <i>DPYD</i> Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. <i>JCO Oncology Practice</i> , 2020, 16, 793-798.	1.4	46
76	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 621-625.	1.0	44
77	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019, 25, 7497-7505.	3.2	44
78	Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type <i>KRAS</i> mCRC Patients. <i>Clinical Cancer Research</i> , 2010, 16, 5591-5602.	3.2	43
79	MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2988-2995.	3.2	42
80	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3505-3505.	0.8	42
81	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 251-266.	1.1	41
82	Clocking cancer: the circadian clock as a target in cancer therapy. <i>Oncogene</i> , 2021, 40, 3187-3200.	2.6	41
83	Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3505-3505.	0.8	41
84	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 1207-1213.	0.6	40
85	Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3506.	0.8	40
86	12â€Chemokine signature, a predictor of tumor recurrence in colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 532-541.	2.3	39
87	Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. <i>Pharmacogenomics Journal</i> , 2018, 18, 29-34.	0.9	38
88	Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance. <i>Cancers</i> , 2020, 12, 1393.	1.7	38
89	Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 528-539.	1.9	37
90	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020, 140, 119-129.	1.3	37

#	ARTICLE	IF	CITATIONS
91	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019, 45, 139-154.	2.7	36
92	Determinants of prognosis and response to therapy in colorectal cancer. <i>Current Oncology Reports</i> , 2001, 3, 102-108.	1.8	35
93	Biomarker in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 156-164.	1.0	35
94	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2012, 118, 1523-1532.	2.0	34
95	Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1BA385-1BA385.	0.8	34
96	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3510-3510.	0.8	34
97	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2723-2733.	3.2	33
98	Human colorectal cancer-on-chip model to study the microenvironmental influence on early metastatic spread. <i>IScience</i> , 2021, 24, 102509.	1.9	33
99	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin $\beta 1$. <i>Science Signaling</i> , 2014, 7, ra58.	1.6	32
100	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 938-946.	2.9	29
101	Practice-changing updates in the adjuvant and metastatic setting. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 77-78.	12.5	29
102	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019, 24, 319-326.	1.9	29
103	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
104	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. <i>Annals of Oncology</i> , 2017, 28, 2780-2785.	0.6	28
105	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	1.1	28
106	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1174-1183.	3.2	28
107	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014, 9, 205-214.	1.7	27
108	Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 897-907.	1.1	27

#	ARTICLE	IF	CITATIONS
109	Evaluating the impact of age on immune checkpoint therapy biomarkers. <i>Cell Reports</i> , 2021, 36, 109599.	2.9	27
110	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 271-279.	3.0	27
111	Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness. <i>Scientific Reports</i> , 2015, 5, 11207.	1.6	26
112	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020, 5, e000942.	2.0	26
113	Pharmacogenomics and Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2006, 587, 211-231.	0.8	26
114	Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA444-LBA444.	0.8	26
115	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3531-3531.	0.8	26
116	Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. <i>Oncotarget</i> , 2016, 7, 53668-53678.	0.8	26
117	Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2401-2408.	1.9	25
118	What We Know About Stage II and III Colon Cancer: It's Still Not Enough. <i>Targeted Oncology</i> , 2017, 12, 265-275.	1.7	25
119	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018, 17, e395-e414.	1.0	25
120	Management of Advanced Small Bowel Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 69.	1.3	25
121	The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 5911-5924.	0.9	25
122	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	1.3	25
123	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 404-413.	1.9	25
124	Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC). <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 43-60.	0.9	24
125	The safety of monoclonal antibodies for treatment of colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 799-808.	1.0	24
126	Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017, 28, 1015-1022.	0.6	24

#	ARTICLE	IF	CITATIONS
127	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713.	3.4	24
128	Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases. <i>Science Advances</i> , 2020, 6, eaba6752.	4.7	24
129	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.	3.2	24
130	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	3.0	24
131	High frequency of simultaneous loss of p16 and p16 ¹² gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach. <i>Oncogene</i> , 1997, 15, 1481-1488.	2.6	23
132	CDX2 as a Prognostic Biomarker in Colon Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 2182-2184.	13.9	23
133	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , 2018, 24, 784-793.	3.2	23
134	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
135	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017, 86, 197-206.	1.3	22
136	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020, 46, 955-966.	0.5	22
137	Prognostic Impact of <i>IL6</i> Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 3218-3226.	3.2	21
138	Predictive value of <i>TLR7</i> polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2017, 141, 1222-1230.	2.3	21
139	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1297-1308.	1.4	21
140	A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1193-1198.	0.6	21
141	Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e741-e749.	1.0	20
142	An Open-Label, Dose- Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 5204-5210.	3.2	19
143	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017, 77, 13-20.	1.3	19
144	DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. <i>Cancer</i> , 2017, 123, 3732-3743.	2.0	19

#	ARTICLE	IF	CITATIONS
145	Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. <i>Clinical Colorectal Cancer</i> , 2018, 17, e121-e125.	1.0	19
146	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1451-1455.	2.9	19
147	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021, 40, 4894-4905.	2.6	19
148	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. <i>European Journal of Cancer</i> , 2020, 133, 66-73.	1.3	19
149	Characterization of tumor mutation load (TML) in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11517-11517.	0.8	19
150	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. <i>Oncogene</i> , 2022, 41, 3455-3460.	2.6	19
151	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 2503.	0.6	18
152	The structure-function relationship of oncogenic LMTK3. <i>Science Advances</i> , 2020, 6, .	4.7	18
153	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	2.9	17
154	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 98.	1.1	17
155	A Multicenter Comparison of Complementary and Alternative Medicine (CAM) Discussions in Oncology Care: The Role of Time, Patient-Centeredness, and Practice Context. <i>Oncologist</i> , 2019, 24, e1180-e1189.	1.9	17
156	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 1320-1328.	0.8	16
157	Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. <i>Clinical Colorectal Cancer</i> , 2021, 20, 84-95.e8.	1.0	15
158	Time course of regorafenib-associated adverse events in the phase III CORRECT study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 467-467.	0.8	15
159	MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 493-493.	0.8	15
160	Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 751-759.	1.5	14
161	Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 4734-4744.	3.2	14
162	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019, 4, e000489.	2.0	14

#	ARTICLE	IF	CITATIONS
163	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2634-2640.	1.9	14
164	VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer. <i>Molecular Oncology</i> , 2021, 15, 2801-2817.	2.1	14
165	Implications of Genetic Testing in the Management of Colorectal Cancer. <i>Molecular Diagnosis and Therapy</i> , 2003, 3, 73-88.	3.3	13
166	Molecular Pathways: Turning Proteasomal Protein Degradation into a Unique Treatment Approach. <i>Clinical Cancer Research</i> , 2014, 20, 3064-3070.	3.2	13
167	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2021, 27, 267-275.	3.2	13
168	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 155, 73-84.	1.3	13
169	Cetuximab in the management of colorectal cancer. <i>Biologics: Targets and Therapy</i> , 2007, 1, 77-91.	3.0	13
170	Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3510-3510.	0.8	13
171	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. <i>Cancer</i> , 2015, 121, 1898-1905.	2.0	12
172	TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1283-1292.	1.1	12
173	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e471-e488.	1.0	12
174	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019, 18, e8-e19.	1.0	12
175	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2019, 107, 100-114.	1.3	12
176	Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. <i>Investigational New Drugs</i> , 2021, 39, 812-820.	1.2	12
177	Reprogramming CBX8-PRC1 function with a positive allosteric modulator. <i>Cell Chemical Biology</i> , 2022, 29, 555-571.e11.	2.5	12
178	Pharmacogenomics and metastatic colorectal cancer: Current knowledge and perspectives. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 325-339.	0.6	11
179	Prospective study of EGFR intron 1 (CA) _n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. <i>Pharmacogenomics Journal</i> , 2014, 14, 322-327.	0.9	11
180	A novel antimetabolite: TAS-102 for metastatic colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 355-365.	1.3	11

#	ARTICLE	IF	CITATIONS
181	<i>TP53</i> Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1405-1411.	1.9	11
182	Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates. <i>Oncologist</i> , 2022, 27, 579-586.	1.9	11
183	Overcoming resistance to anti-EGFR therapy "where do we stand?". <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 258-259.	8.2	10
184	Single nucleotide polymorphisms in the IGF1R pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. <i>International Journal of Cancer</i> , 2017, 141, 383-392.	2.3	10
185	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	1.7	10
186	Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECURSE trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2579-2579.	0.8	10
187	Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. <i>Oncotarget</i> , 2019, 10, 7016-7030.	0.8	10
188	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1091-1108.	1.3	9
189	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2814-2821.	1.9	9
190	Clinical Significance of <i>TLR1</i> 1602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1740-1745.	1.9	9
191	Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. <i>Clinical Colorectal Cancer</i> , 2016, 15, e221-e227.	1.0	9
192	Biomarker-driven and molecular targeted therapies for colorectal cancers. <i>Seminars in Oncology</i> , 2018, 45, 124-132.	0.8	9
193	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020, 131, 89-97.	1.3	9
194	Impacts of the SARS-CoV-2 Pandemic on Young Adult Colorectal Cancer Survivors. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 229-233.	0.7	9
195	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 95.	2.3	9
196	Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response. <i>Frontiers in Oncology</i> , 2021, 11, 771173.	1.3	9
197	Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2538-2538.	0.8	9
198	Tandem repeat variation near the <i>HIC1</i> (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017, 123, 4506-4514.	2.0	8

#	ARTICLE	IF	CITATIONS
199	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018, 18, 623-632.	0.9	8
200	High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. <i>PLoS ONE</i> , 2019, 14, e0219469.	1.1	8
201	Genetic variants in <i>CCL5</i> and <i>CCR5</i> genes and serum VEGF levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. <i>International Journal of Cancer</i> , 2019, 144, 2567-2577.	2.3	8
202	Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. <i>Cancer Science</i> , 2020, 111, 441-450.	1.7	8
203	Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. <i>International Journal of Cancer</i> , 2022, 150, 279-289.	2.3	8
204	Clinical Significance of Circulating Tumor Cell Induced Epithelial-Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single-Cell RNA-Sequencing. <i>Cancers</i> , 2021, 13, 4862.	1.7	8
205	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012, 23, 1370-1371.	0.6	7
206	The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. <i>Pharmacogenomics</i> , 2017, 18, 197-200.	0.6	7
207	Risk of Persistent Opioid Use following Major Surgery in Matched Samples of Patients with and without Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2126-2133.	1.1	7
208	Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 4756-4766.	3.2	7
209	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. <i>Targeted Oncology</i> , 2021, 16, 517-527.	1.7	7
210	Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). <i>Journal of Clinical Oncology</i> , 2012, 30, 260-260.	0.8	7
211	Molecular characterization of squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2423-2437.	0.6	7
212	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. <i>Oncogene</i> , 2022, 41, 260-267.	2.6	7
213	Partition: a surjective mapping approach for dimensionality reduction. <i>Bioinformatics</i> , 2020, 36, 676-681.	1.8	6
214	Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). <i>Cancer</i> , 2021, 127, 3801-3808.	2.0	6
215	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	2.9	6
216	So Much Effort, So Little Progress?. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	5

#	ARTICLE	IF	CITATIONS
217	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS ONE, 2018, 13, e0193640.	1.1	5
218	A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. International Journal of Cancer, 2019, 145, 2450-2458.	2.3	5
219	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS ONE, 2020, 15, e0239439.	1.1	5
220	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Scientific Reports, 2020, 10, 9778.	1.6	5
221	The Emergence of Baricitinib: A Story of Tortoises Versus Hares. Clinical Infectious Diseases, 2021, 72, 1251-1252.	2.9	5
222	MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.. Journal of Clinical Oncology, 2016, 34, 3515-3515.	0.8	5
223	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. Journal of Cancer Metastasis and Treatment, 2018, 4, 12.	0.5	5
224	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 2374-2381.	1.9	4
225	Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics, 2018, 17, 2788-2795.	1.9	4
226	Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. Clinical Colorectal Cancer, 2018, 17, 215-222.e3.	1.0	4
227	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. European Journal of Cancer, 2019, 111, 138-147.	1.3	4
228	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. International Journal of Cancer, 2019, 145, 2082-2090.	2.3	4
229	Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers, 2020, 12, 2947.	1.7	4
230	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers, 2020, 12, 1742.	1.7	4
231	Microsatellite Stable Colorectal Liver Metastases—Understanding the Mechanisms of Immune Resistance. JAMA Network Open, 2021, 4, e2119025.	2.8	4
232	Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy. Journal of Controlled Release, 2021, 336, 433-442.	4.8	4
233	Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. Cancer Genomics and Proteomics, 2021, 18, 317-324.	1.0	4
234	Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 3029-3029.	0.8	4

#	ARTICLE	IF	CITATIONS
235	Association of Homologous Recombinationâ€“DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 227-236.	1.9	4
236	fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing. <i>Bioinformatics Advances</i> , 2022, 2, .	0.9	4
237	Individualization of therapy based on clinical and molecular parameters. <i>Current Colorectal Cancer Reports</i> , 2008, 4, 193-200.	1.0	3
238	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 519-531.	1.4	3
239	Reply: Comment on â€“Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumabâ€™. <i>British Journal of Cancer</i> , 2013, 109, 3129-3130.	2.9	3
240	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO. <i>Annals of Oncology</i> , 2016, 27, vi152.	0.6	3
241	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2021, 21, 285-295.	0.9	3
242	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021, 11, 12191.	1.6	3
243	A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 100-100.	0.8	3
244	The Molecular Taxonomy of Colorectal Cancer: Whatâ€™s New?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 118-124.	1.0	2
245	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 580-590.	0.3	2
246	Novel Genomic Differences in Cell-Free Circulating DNA Profiles of Young- Versus Older-Onset Colorectal Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 10, 336-341.	0.7	2
247	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3532-3532.	0.8	2
248	LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS794-TPS794.	0.8	2
249	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12106-12106.	0.8	2
250	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3576-3576.	0.8	2
251	Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 10-16.	0.7	2
252	Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA) Tj ETQq0 0 0 rgBT /Overlock 10 diagnosed metastatic colorectal cancer (GRANITE).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3635-TPS3635.	0.8	2

#	ARTICLE	IF	CITATIONS
253	The tumor microenvironment and immune infiltration landscape of <i>KRAS</i> mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC).. Journal of Clinical Oncology, 2022, 40, 4142-4142.	0.8	2
254	CXCR4 overexpression: An indicator of poor survival and predictor of response to immunotherapy in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3546-3546.	0.8	2
255	Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 4018-4018.	0.8	2
256	Can we predict the response to epidermal growth factor receptor targeted therapy?. Targeted Oncology, 2008, 3, 87-99.	1.7	1
257	Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy. Current Colorectal Cancer Reports, 2012, 8, 263-271.	1.0	1
258	P-198 Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib. Annals of Oncology, 2015, 26, iv57.	0.6	1
259	Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2016, 100, 117-126.	2.0	1
260	Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. Scientific Reports, 2021, 11, 5639.	1.6	1
261	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Molecular Cancer Therapeutics, 2021, 20, 1153-1160.	1.9	1
262	Single cell RNA-sequence analysis to identify transcriptomic differences associated with treatment outcome and ethnicity in circulating tumor cells (CTCs) from patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2021, 39, 3041-3041.	0.8	1
263	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. European Journal of Cancer, 2021, 150, 133-142.	1.3	1
264	MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, TPS3635-TPS3635.	0.8	1
265	Genetic variations within the vitamin C transporter genes to predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.. Journal of Clinical Oncology, 2017, 35, 11507-11507.	0.8	1
266	Association of immune-related genes to neutrophil-lymphocyte ratio (NLR) with survival of cetuximab treatment for metastatic colorectal cancer (mCRC): JACCRO CC-05/06AR.. Journal of Clinical Oncology, 2017, 35, 11613-11613.	0.8	1
267	Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer. British Journal of Cancer, 2021, , .	2.9	1
268	Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.. Journal of Clinical Oncology, 2017, 35, 3528-3528.	0.8	1
269	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2019, 37, 3048-3048.	0.8	1
270	The differential response to immune checkpoint inhibitors in colorectal and endometrial cancer patients according to different mismatch repair alterations.. Journal of Clinical Oncology, 2022, 40, 3625-3625.	0.8	1

#	ARTICLE	IF	CITATIONS
271	Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.. Journal of Clinical Oncology, 2022, 40, 3572-3572.	0.8	1
272	Claudin 18 (<i>CLDN18</i>) gene expression and related molecular profile in gastric cancer (GC).. Journal of Clinical Oncology, 2022, 40, 4048-4048.	0.8	1
273	Using The Colon Cancer Multigene Recurrence Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction?. Current Colorectal Cancer Reports, 2010, 6, 183-192.	1.0	0
274	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	1.0	0
275	Tandem repeat variation in HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, vi38.	0.6	0
276	VEGF Ligands. , 2017, , 639-658.		0
277	New perspectives for colorectal cancer. Oncotarget, 2017, 8, 41782-41783.	0.8	0
278	Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 12098-12098.	0.8	0
279	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. Journal of Clinical Oncology, 2018, 36, 4098-4098.	0.8	0
280	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. Journal of Clinical Oncology, 2019, 37, 564-564.	0.8	0
281	Comprehensive molecular analysis of microsatellite-stable (MSS) tumors with high mutational burden in gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2020, 38, 3631-3631.	0.8	0
282	Molecular correlates of PD-L1 expression in patients (pts) with gastroesophageal (GE) cancers.. Journal of Clinical Oncology, 2020, 38, 4558-4558.	0.8	0
283	LRP1B and GRM3 expression in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 177-177.	0.8	0
284	Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2022, 40, 246-246.	0.8	0
285	KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors. Clinical Advances in Hematology and Oncology, 2008, 6, 1-13, 14-6.	0.3	0
286	Molecular correlates of <i>MAEA</i> expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3128-3128.	0.8	0
287	Abstract 5699: Overexpression of KMT2A is associated with worse prognosis and specific immune signatures in patients with TP53-mutated hepatocellular carcinomas. Cancer Research, 2022, 82, 5699-5699.	0.4	0
288	Comprehensive profiling of clock genes expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3129-3129.	0.8	0

#	ARTICLE	IF	CITATIONS
289	Characterization of TIM3 and its ligands in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3547-3547.	0.8	0
290	Predictive value of <i>CDC37</i> gene expression for targeted therapy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, 3586-3586.	0.8	0
291	Predictive value of <i>MAOB</i> gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405.. Journal of Clinical Oncology, 2022, 40, 3580-3580.	0.8	0
292	Interplay between B cell and GABA metabolism (GABA _m) and association with immune evasion in breast carcinoma (BC).. Journal of Clinical Oncology, 2022, 40, 1097-1097.	0.8	0
293	Comprehensive characterization of <i>PTPRT</i> expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3538-3538.	0.8	0
294	Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2022, 40, 3553-3553.	0.8	0
295	<i>DEFB1</i> gene expression and the molecular landscape of colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3523-3523.	0.8	0
296	Landscape of endocytosis pathway in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3148-3148.	0.8	0
297	The prognostic significance of <i>TP53</i> mutations in patients with right-sided and left-sided colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3589-3589.	0.8	0
298	Characterization of <i>NY-ESO-1</i> gene expression in gastric cancer (GC).. Journal of Clinical Oncology, 2022, 40, 4046-4046.	0.8	0